bacampicillin and Bronchitis

Nine hundred and eleven patients were admitted to a multicentre trial with bacampicillin (Penglobe) in respiratory tract infections. Of these it was possible to evaluate 830 with respect to efficacy and side-effects. In most cases a dosage of 400 mg X 2 was used but in severe cases 800 mg X 2 was used. The clinical outcome was assessed as good for 79% of the patients, while 17% showed an improvement and 3% a failure. The tolerance was good with an over-all incidence of 8% side-effects, of which dyspepsia was the most common.

Topics: Ampicillin; Belgium; Bronchitis; Bronchopneumonia; Clinical Trials as Topic; Drug Eruptions; Drug Tolerance; Dyspepsia; Family Practice; Humans; Otitis Media; Respiratory Tract Infections; Tonsillitis

Topics: Acute Disease; Adolescent; Adult; Ampicillin; Bronchitis; Female; Humans; Male

A clinical trial of bacampicillin was carried out in 20 patients. The antibiotic was found to be effective in acute lobar pneumonia, pyogenic meningitis, acute and chronic bronchitis, acute pharyngitis, acute tonsillitis, cellulitis, furunculosis, and pyomyositis caused by such ampicillin-sensitive organisms as Neisseria meningitidis, Diplococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Streptococcus pyogenes, Klebsiella pneumoniae, and Escherichia coli. Rash in three patients was the only side effect encountered. It is concluded that while bacampicillin may have overcome some of the disadvantages of ampicillin, it retains its main attributes and some shortcomings.

Topics: Adolescent; Adult; Aged; Ampicillin; Bacterial Infections; Bronchitis; Cellulitis; Child; Clinical Trials as Topic; Female; Furunculosis; Haemophilus Infections; Humans; Male; Meningitis; Middle Aged; Pharyngitis; Pneumonia, Pneumococcal; Respiratory Tract Infections; Staphylococcal Infections; Streptococcal Infections; Tonsillitis

Topics: Ampicillin; Bronchitis; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Haemophilus Infections; Humans

Topics: Adult; Aged; Ampicillin; Bronchitis; Chronic Disease; Clinical Trials as Topic; Female; Haemophilus influenzae; Humans; Male; Middle Aged; Sputum; Time Factors

Topics: Amoxicillin; Ampicillin; Bronchitis; Chronic Disease; Humans; Respiratory Tract Infections; Spain

There are references in the literature describing the influence of bronchial inflammation on the antibiotic concentration in bronchial secretions, including netilmicin concentrations in the bronchial secretion of patients undergoing tracheotomy. Three semi-synthetic penicillins are compared--bacampicillin, amoxicillin and talampicillin--administered frequently in the treatment of various respiratory infections. The three antibiotics were administered successively for two days each, in the same patient, irrespective of other drugs. At the same time the cytologic evaluation of the degree of bronchial inflammation was done. The antibiotic concentrations in bronchial secretions and in sera were measured at the same time. The results showed that the concentration of antibiotics in bronchial secretions of patients undergoing tracheotomy was proportional to the degree of bronchial inflammation. Among the semi-synthetic penicillins investigated the highest degree of concentration in the bronchial secretion was obtained after the bacampicillin.

Topics: Amoxicillin; Ampicillin; Bronchi; Bronchitis; Humans; Talampicillin; Time Factors

Clinical research was conducted to evaluate the comparative therapeutic efficacy in respiratory pathology of 800 mg X 2 per diem bacampicillin v. 1000 mg X 2 per diem amoxicillin, both orally administered. The results were more or less identical and are interpreted as indicating the better constant absorption of the precursor, hence its higher concentration gradient that produces a higher antibiotic concentration in the lungs.

Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Ampicillin; Bacteria; Bacterial Infections; Bronchitis; Bronchopneumonia; Female; Humans; Male; Middle Aged; Respiratory Tract Infections

Topics: Acute Disease; Adult; Aged; Ampicillin; Bronchitis; Female; Humans; Male; Middle Aged; Sinusitis

Topics: Adult; Ampicillin; Bronchitis; Chronic Disease; Humans; Kinetics; Middle Aged

Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Bronchitis; Drug Therapy, Combination; Humans; Kinetics; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Suppuration

The purpose of the study was to select the minimum effective dose of bacampicillin in a systematic dose-response study in hospitalised patients with acute exacerbations of chronic bronchitis. In all 37 patients Haemophilus influenzae or H. parainfluenzae was isolated from purulent sputum before treatment with 400, 800 or 1200 mg of bacampicillin twice daily for 10 days. There was a significant relationship between the administered dose and clinical results at the end of treatment (P less than 0.01) as well as 1 week later (P less than 0.02). The results show that bacampicillin given twice daily is effective in the treatment of acute bacterial exacerbations of chronic bronchitis, with a minimum effective dose of 800 mg twice daily. A rash was noted in one patient.

Topics: Ampicillin; Bronchitis; Chronic Disease; Dose-Response Relationship, Drug; Haemophilus Infections; Humans; Microbial Sensitivity Tests; Sputum

We investigated bacampicillin (BAPC) granules in the field of pediatrics. 1) Average serum levels after administration of BAPC granules at a dose of 10 mg/kg as ABPC were 6.8 mug/ml at 1 hour, 1.4 mug/ml at 6 hours. Average urinary excretion rate till 6 hours was 84.5%. Those results were almost same as those obtained with BAPC tablet. 2) We treated patients with acute tonsillitis, lacunar tonsillitis and acute bronchitis by BAPC granules at a dose of 30 approximately 40 mg potency/kg for 3 approximately 5 days, and excellent results were obtained. 3) In the case of streptococcal infections including scarlet fever, pharyngeal streptococci disappeared 1 approximately 2 days after administration and did not reappeared. 4) BAPC granules were easy to intake for children and no abnormal laboratory finding was observed. 5) BAPC granules seem to be useful for treatment of pediatric infections.

Topics: Acute Disease; Ampicillin; Bronchitis; Dosage Forms; Humans; Scarlet Fever; Tonsillitis

In an open multicentre study of bacampicillin (Penglobe), a new orally well absorb ed prodrug of ampicillin, 516 patients with acute exacerbations of chronic bronchitis or pneumonia were treated by a group of Belgian pneumologists or internists. Bacampicillin was given in a dosage regimen of 400 mg or 800 mg three times daily. In patients with acute exacerbations of chronic bronchitis the clinical success rate was high, over 95% in both groups. An improvement in the sputum purulence score was seen in 93% of the patients with an initially purulent sputum and 69% had a normal mucoid sputum at follow-up. The clinical success rate in patients with pneumonia was also similar in both dosage groups with success rates over 96%. The total number of patients with adverse reactions was not more than 5-4%, of which the majority were considered mild or moderate. Each type of side-effect occurred in a frequency of 1-2% or less. There were no differences between the two dosage regiments as regards the frequency of side-effects indicates a remarkably good tolerance of bacampicillin also with the higher dosage.

Topics: Acute Disease; Adult; Aged; Ampicillin; Bronchitis; Chronic Disease; Female; Humans; Male; Middle Aged; Pneumonia